ascopubs.org

A global comparative study on MDT practices in the management of hepatocellular carcinoma in high-income countries (HICs) and low- and middle-income countries (LMICs).

The impact of adherence to NCCN and BCLC treatment guidelines on survival in HCC: A single center study. 10 key areas highlighting differences identified between HICs and LMICs. MDT development ...
ascopubs.org

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. This is an ASCO Meeting Abstract from the ...
ascopubs.org

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI ...

Advantages of minimally invasive surgery for remnant gastric cancer: A multi-institutional cohort study. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This ...
ascopubs.org

Primary results of ANZ 1002: Post-operative radiotherapy omission in selected patients with early breast cancer trial (PROSPECT) following pre-operative breast MRI.

Mode of detection of second breast cancers in patients undergoing surveillance after treatment of ductal carcinoma in situ. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
ascopubs.org

Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of ...

Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
ascopubs.org

Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. Randomized phase 2 study of gemcitabine with or ...
ascopubs.org

The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.

RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
ascopubs.org

Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer.

Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
ascopubs.org

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering ...
ascopubs.org

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

The FLAME trial hypothesized that focal boosting of intraprostatic tumor lesion(s) in addition to standard external beam radiotherapy (EBRT) improves biochemical disease-free survival (bDFS). In this ...
ascopubs.org

Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.

Targeting urothelial neoplasia using an investigational virus-like drug conjugate. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This abstract does not include a ...
ascopubs.org

Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.

A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.